Literature DB >> 12606712

Crystal structure of the receptor-binding domain of human B7-2: insights into organization and signaling.

Xuewu Zhang1, Jean-Claude D Schwartz, Steven C Almo, Stanley G Nathenson.   

Abstract

B7-1 and B7-2 are homologous costimulatory ligands expressed on the surfaces of antigen-presenting cells. Their interactions with CD28/CTLA-4 receptors expressed on T cell surfaces are crucial for the proper regulation of T cell activity. B7-1 and B7-2 display distinct roles in immune regulation, although they are usually considered to have redundant functions. Here, we report the crystal structure of the receptor-binding (Ig V-type) domain of human B7-2 at 2.7-A resolution. Structures of unliganded and liganded B7-1 and B7-2 suggest a physical-chemical basis for the observed functional similarities and differences between these two costimulatory ligands. Of particular note, whereas the majority of the residues mediating B7-1 dimerization are hydrophobic, the B7-2 dimer observed in the B7-2/CTLA-4 complex displays a very hydrophilic dimer interface. These differences provide a mechanism for preventing the formation of B7-1/B7-2 heterodimers. The divergence at the putative dimer interface is also consistent with the lower tendency of B7-2 to dimerize, as shown by the monomeric state of unliganded B7-2 both in solution and crystalline form, and may result in detailed differences in signaling mechanisms associated with B7-1 and B7-2.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12606712      PMCID: PMC151384          DOI: 10.1073/pnas.252771499

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons.

Authors:  A Nicholls; K A Sharp; B Honig
Journal:  Proteins       Date:  1991

2.  B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy.

Authors:  V K Kuchroo; M P Das; J A Brown; A M Ranger; S S Zamvil; R A Sobel; H L Weiner; N Nabavi; L H Glimcher
Journal:  Cell       Date:  1995-03-10       Impact factor: 41.582

3.  CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines.

Authors:  C B Thompson; T Lindsten; J A Ledbetter; S L Kunkel; H A Young; S G Emerson; J M Leiden; C H June
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

4.  B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells.

Authors:  G J Freeman; A S Freedman; J M Segil; G Lee; J F Whitman; L M Nadler
Journal:  J Immunol       Date:  1989-10-15       Impact factor: 5.422

5.  Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1.

Authors:  J H Brown; T S Jardetzky; J C Gorga; L J Stern; R G Urban; J L Strominger; D C Wiley
Journal:  Nature       Date:  1993-07-01       Impact factor: 49.962

6.  SETOR: hardware-lighted three-dimensional solid model representations of macromolecules.

Authors:  S V Evans
Journal:  J Mol Graph       Date:  1993-06

7.  CTLA-4 can function as a negative regulator of T cell activation.

Authors:  T L Walunas; D J Lenschow; C Y Bakker; P S Linsley; G J Freeman; J M Green; C B Thompson; J A Bluestone
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

8.  Crystal structure of the extracellular region of the human cell adhesion molecule CD2 at 2.5 A resolution.

Authors:  D L Bodian; E Y Jones; K Harlos; D I Stuart; S J Davis
Journal:  Structure       Date:  1994-08-15       Impact factor: 5.006

9.  Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.

Authors:  G J Freeman; J G Gribben; V A Boussiotis; J W Ng; V A Restivo; L A Lombard; G S Gray; L M Nadler
Journal:  Science       Date:  1993-11-05       Impact factor: 47.728

10.  Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.

Authors:  P S Linsley; J L Greene; W Brady; J Bajorath; J A Ledbetter; R Peach
Journal:  Immunity       Date:  1994-12       Impact factor: 31.745

View more
  28 in total

1.  BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation.

Authors:  Thang Nguyen; Xikui K Liu; Yongliang Zhang; Chen Dong
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

Review 2.  Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells.

Authors:  Hélène Bour-Jordan; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

3.  Superantigens hyperinduce inflammatory cytokines by enhancing the B7-2/CD28 costimulatory receptor interaction.

Authors:  Revital Levy; Ziv Rotfogel; Dalia Hillman; Andrey Popugailo; Gila Arad; Emmanuelle Supper; Farhat Osman; Raymond Kaempfer
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-05       Impact factor: 11.205

Review 4.  Checkpoint blockade in cancer immunotherapy.

Authors:  Alan J Korman; Karl S Peggs; James P Allison
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

Review 5.  Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family.

Authors:  Hélène Bour-Jordan; Jonathan H Esensten; Marc Martinez-Llordella; Cristina Penaranda; Melanie Stumpf; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

6.  A dimeric structure of PD-L1: functional units or evolutionary relics?

Authors:  Yong Chen; Peipei Liu; Feng Gao; Hao Cheng; Jianxun Qi; George F Gao
Journal:  Protein Cell       Date:  2010-02-06       Impact factor: 14.870

7.  Cowpox virus encodes a protein that binds B7.1 and B7.2 and subverts T cell costimulation.

Authors:  Xiaoli Wang; Sytse J Piersma; Jabari I Elliott; John M Errico; Maria D Gainey; Liping Yang; Christopher A Nelson; Wayne M Yokoyama; Daved H Fremont
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-01       Impact factor: 11.205

Review 8.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

9.  The molecular basis for modulation of human Vγ9Vδ2 T cell responses by CD277/butyrophilin-3 (BTN3A)-specific antibodies.

Authors:  Aparna Palakodeti; Andrew Sandstrom; Lakshmi Sundaresan; Christelle Harly; Steven Nedellec; Daniel Olive; Emmanuel Scotet; Marc Bonneville; Erin J Adams
Journal:  J Biol Chem       Date:  2012-07-30       Impact factor: 5.157

Review 10.  CD28 Costimulation: From Mechanism to Therapy.

Authors:  Jonathan H Esensten; Ynes A Helou; Gaurav Chopra; Arthur Weiss; Jeffrey A Bluestone
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.